Meta-Analysis of 11 Heterogeneous Studies regarding Dipeptidyl Peptidase 4 Inhibitor Add-On Therapy for Type 2 Diabetes Mellitus Patients Treated with Insulin
Background. Several clinical trials have addressed the therapeutic strategy of adding dipeptidyl peptidase 4 (DPP-4) inhibitors to the treatment of type 2 diabetes mellitus (DM) inadequately controlled by insulin therapy. However, there is a high degree of heterogeneity in these studies, and the cau...
Main Authors: | Katsuya Shibuki, Shuji Shimada, Takao Aoyama |
---|---|
Format: | Article |
Language: | English |
Published: |
Hindawi Limited
2020-01-01
|
Series: | Journal of Diabetes Research |
Online Access: | http://dx.doi.org/10.1155/2020/6321826 |
Similar Items
-
Dipeptidyl peptidase-4 inhibitors as add-on therapy to insulin in patients with type 2 diabetes mellitus: a meta-analysis of randomized controlled trials
by: Wang N, et al.
Published: (2019-08-01) -
Dipeptidyl peptidase-4 inhibitors or sodium glucose co-transporter-2 inhibitors as an add-on to insulin therapy: A comparative review
by: Awadhesh Kumar Singh, et al.
Published: (2016-01-01) -
Association between Add-On Dipeptidyl Peptidase-4 Inhibitor Therapy and Diabetic Retinopathy Progression
by: Eugene Yu-Chuan Kang, et al.
Published: (2021-06-01) -
Effects of Combination Treatment With Dipeptidyl Peptidase IV Inhibitor and Sulfonylurea on Glucose Levels in Rats
by: Kotaro Takasaki, et al.
Published: (2004-01-01) -
Renoprotective Effect of Dipeptidyl Peptidase-4 Inhibitors in Patients with Type 2 Diabetes Mellitus
by: Hiroki Esaki, et al.
Published: (2017-11-01)